Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor – An Update

Jakubowska A, Roux CWL, Viljoen A. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor – An Update Endocrinol Metab (Seoul)

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis Obesity (Silver Spring)

A review of the evidence on cardiovascular outcomes from obesity treatment

Abdul Wahab R, le Roux CW. A review of the evidence on cardiovascular outcomes from obesity treatment Obes Pillars

Obesity drug shortages are symptomatic of wider malaise

Sumithran P, Finucane FM, Cohen RV. Obesity drug shortages are symptomatic of wider malaise Lancet

Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population

Buckley A, Suliman S, Allum M, Mohammed N, Lessan N, le Roux CW, Suliman M. Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population Diabetes Obes Metab
Insulin Resistance & Diabetes

NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?

Lafferty RA, Flatt PR, Irwin N. NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management? Peptides
Genetics Gut-Brain Insulin Resistance & Diabetes

Editorial: The rise and rise of peptide therapeutics for obesity-diabetes

Flatt PR, Conlon JM. Editorial: The rise and rise of peptide therapeutics for obesity-diabetes Peptides

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?

Lafferty RA, Flatt PR, Gault VA, Irwin N. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes? J Endocrinol

Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus

Anyiam O, Phillips B, Quinn K, Wilkinson D, Smith K, Atherton P, Idris I. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus Clin Nutr
Insulin Resistance & Diabetes

Impact of insulin sensitization on metabolic and fertility outcomes in women with polycystic ovary syndrome and overweight or obesity-A systematic review, meta-analysis, and meta-regression

Samarasinghe SNS, Ostarijas E, Long MJ, Erridge S, Purkayastha S, Dimitriadis GK, Miras AD. Impact of insulin sensitization on metabolic and fertility outcomes in women with polycystic ovary syndrome and overweight or obesity-A systematic review, meta-analysis, and meta-regression Obes Rev
PCOS

Older posts

Newer posts

← Previous Page1 … Page11 Page12 Page13 … Page30 Next →

Search for:

Recent Posts

Experts encourage ‘whole of health’ approach to obesity treatment
10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI